Company intelligence / Profile preview

XenTech

Évry, Île-de-France, Francexentech.eu ↗

Ownership: Private
Employees: ~32
Development stage: Commercial

Overview

XenTech does not conduct clinical trials itself but supports preclinical evaluation. Their PDX models are widely used by pharma/biotech companies and academic centers to predict efficacy and identify biomarkers before entering the clinic. They are recognized for accelerating translational oncology research, especially in precision medicine and pediatric oncology through ITCC-P4 collaboration.

Therapeutic areas: Oncology
Modalities: Patient-derived tumor xenograft models (PDX)Small molecule (as tested compounds)Biologic (as tested compounds)
Industry: Drug Discovery Services

Partnerships

Institut CurieGustave Roussy Cancer CenterITCC-P4 gGmbH

Beyond the preview

Go deeper on XenTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XenTech.

Explore the full profile